Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02387853
Recruitment Status : Completed
First Posted : March 13, 2015
Results First Posted : January 15, 2019
Last Update Posted : January 15, 2019
Sponsor:
Information provided by (Responsible Party):
LEO Pharma

Brief Summary:
An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.

Condition or disease Intervention/treatment Phase
Psoriasis Vulgaris Drug: LEO 90100 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 117 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Actual Study Start Date : March 2016
Actual Primary Completion Date : March 28, 2018
Actual Study Completion Date : March 28, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: LEO 90100 Drug: LEO 90100



Primary Outcome Measures :
  1. Number of Subjects With Adverse Events (AEs) [ Time Frame: From Week -1 to Week 8 ]
    Number of subjects with adverse events in the safety analysis set, defined by excluding subjects from the full analysis set who either received no treatment with the IMP and/or for whom no post-baseline safety evaluations are available.

  2. Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After ACTH-challenge at Week 4 [ Time Frame: 30 minutes after ACTH-challenge at Week 4 ]
    Number of subjects with serum cortisol concentration of ≤18 mcg/dl at 30 minutes after ACTH-challenge at Week 4 in the per protocol analysis set, defined as all subjects from the full analysis set who were in the HPA axis cohort but excluding subjects who did not receive any treatment with the IMP, did not provide any results for the HPA axis test at Week 4, or did not meet the inclusion criterion concerning evidence of normal adrenal function at baseline.

  3. Change in Albumin-corrected Serum Calcium From Baseline to Week 4 [ Time Frame: From baseline to Week 4 ]
    Change in albumin-corrected serum calcium from baseline to Week 4 in safety analysis set. The safety analysis set, defined by excluding subjects from the full analysis set who either received no treatment with the IMP and/or for whom no post-baseline safety evaluations are available.

  4. Change in Calcium Excretion in 24-hour Urine From Baseline to Week 4 [ Time Frame: From baseline to Week 4 ]
    Change in calcium excretion in 24-hour urine collection from baseline to Week 4 in the 24-hour urine HPA set, defined as all subjects in the safety analysis set. The safety analysis set is defined, according to the Consolidated Trial Protocol, by excluding subjects from the full analysis set who either received no treatment with the IMP and/or for whom no post-baseline safety evaluations are available.

  5. Change in Calcium:Creatinine Ratio in 24-hour Urine From Baseline to Week 4 [ Time Frame: From baseline to Week 4 ]
    Change in calcium:creatinine ratio in 24-hour urine collection from baseline to Week 4 in the 24-hour urine in HPA set, defined as all subjects in the safety analysis set who underwent HPA-axis testing.


Secondary Outcome Measures :
  1. Number of Subjects With Serum Cortisol Concentration ≤18 mcg/dL at Both 30 and 60 Minutes After ACTH-challenge at Week 4 [ Time Frame: 30 and 60 minutes after ACTH-challenge at Week 4 ]
    Number of subjects with serum cortisol concentration ≤18 mcg/dL at both 30 and 60 minutes after ACTH-challenge at Week 4 in the per protocol analysis set, defined as all subjects from the full analysis set who were in the HPA axis cohort but excluding subjects who did not receive any treatment with the IMP, did not provide any results for the HPA axis test at Week 4, or did not meet the inclusion criterion concerning evidence of normal adrenal function at baseline.

  2. Change in Calcium:Creatinine Ratio in Spot Urine Samples From Baseline to Week 4 [ Time Frame: From baseline to Week 4 ]
    Change in calcium:creatinine ratio in spot urine samples from baseline to Week 4 in the spot urine non-HPA set, defined as all subjects in the safety analysis set who did not undergo HPA-axis testing.

  3. Number of Subjects With 'Treatment Success' According to Physician's Global Assessment (PGA) on Body [ Time Frame: Week 4 ]
    Number of subjects with 'treatment success' according to Physician's Global Assessment (PGA) on Body in the full analysis set, defined as the 106 subjects assigned to treatment. Treatment success was defined as 'clear' or 'almost clear' for subjects with at least 'moderate' disease at baseline according to the PGA, and defined as 'clear' for subjects with mild disease at baseline according to the PGA.

  4. Number of Subjects With 'Treatment Success' According to Physician's Global Assessment (PGA) on Scalp [ Time Frame: Week 4 ]
    Number of subjects with 'treatment success' according to Physician's Global Assessment (PGA) on Scalp in the full analysis set, defined as the 106 subjects assigned to treatment. Treatment success was defined as 'clear' or 'almost clear' for subjects with at least 'moderate' disease at baseline according to the PGA, and defined as 'clear' for subjects with mild disease at baseline according to the PGA.

  5. Percentage Change in PASI From Baseline to Week 4 [ Time Frame: From baseline to Week 4 ]
    Percentage change in Psoriasis area and severity index (PASI) score from baseline to Week 4. Psoriasis area and severity index (PASI) assesses extent and severity of clinical signs of psoriasis vulgaris. Body surface is divided in 4 ares: head (incl. neck), arms (incl. hands), trunk (incl. flexures) and legs (incl. buttocks and feet). Each area is scored from 0-6 for extent of psoriasis and from 0-4 for redness, thickness, and scaliness, and an area PASI score is calculated. The total PASI score is calculated from each area's score. The PASI score ranges from 0 (clear skin) to 72 (maximum disease), a PASI score higher than 10 generally corresponds to moderate-to-severe disease.

  6. Number of Subjects With 'Treatment Success' According to the Subject's Global Assessment of Disease Severity on the Body at Week 4 [ Time Frame: Week 4 ]
    Number of subjects with 'treatment success' according to the Subject's Global Assessment of disease severity on the body at Week 4 in the full analysis set, defined as the 106 subjects assigned to treatment. Treatment success was defined as 'clear' or 'very mild' according to the Subject's Global Assessment of disease severity.

  7. Number of Subjects With 'Treatment Success' According to the Subject's Global Assessment of Disease Severity on the Scalp at Week 4 [ Time Frame: Week 4 ]
    Number of subjects with 'treatment success' according to the Subject's Global Assessment of disease severity on the scalp at Week 4 in the full analysis set, defined as the 106 subjects assigned to treatment. Treatment success was defined as 'clear' or 'very mild' according to the Subject's Global Assessment of disease severity.

  8. Change in Itch as Assessed on a Visual Analog Scale (VAS) From Baseline to Week 4 [ Time Frame: From baseline to Week 4 ]
    Change in itch as assessed on a visual analog scale (VAS) from baseline to Week 4 in the full analysis set, defined as the 106 subjects assigned to treatment. The assessments were made on a 100 mm (100 mm = 10 cm) horizontal VAS anchored at 0 ('no itch at all') and 10 ('worst itch you can imagine'). Subjects were asked to put a vertical line on the scale at the spot he/she felt best reflected the maximal itch intensity during the last 24 hours. The distance from 0 to the subject's indication line was measured in mm, thus higher scores indicated a worse outcome.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (all subjects)

  • Psoriasis vulgaris on trunk and/or limbs affecting at least 2% BSA.
  • Psoriasis vulgaris on the scalp affecting at least 10% of total scalp area.
  • A total psoriatic involvement on trunk, limbs and scalp not exceeding 30% BSA.
  • PGA score of at least mild on trunk and/or limbs at SV1, SV2 and V1.
  • PGA score of at least mild on scalp at SV1, SV2 and V1.
  • A serum albumin-corrected calcium below the upper reference limit at SV2.

Inclusion Criteria (for subjects performing HPA axis assessment)

  • Psoriasis vulgaris on trunk and/or limbs affecting at least 10% BSA.
  • Psoriasis vulgaris on the scalp affecting at least 20% of total scalp area.
  • PGA score of at least moderate on trunk and limbs at SV1, SV2 and V1.
  • PGA score of at least moderate on scalp at SV1, SV2 and V1.
  • Normal HPA axis function at SV2 (serum cortisol concentration above 5 mcg/dl before ACTH challenge and serum cortisol concentration above 18 mcg/dl 30 minutes after ACTH challenge).

Exclusion Criteria (all subjects):

  • A history of hypersensitivity to any component of LEO 90100.
  • Systemic treatment with biological therapies (marketed or not marketed), with a possible effect on scalp and/or body psoriasis within the following time period prior to V1 and during the trial:

    1. etanercept - within 4 weeks prior to V1
    2. adalimumab, infliximab - within 2 months prior to V1
    3. ustekinumab - within 4 months prior to V1
    4. experimental products - within 4 weeks/5 half-lives (whichever is longer) prior to V1
  • Systemic treatment with therapies other than biologicals, with a possible effect on scalp and/or body psoriasis (e.g. methotrexate, retinoids, immunosuppressants) within 4 weeks prior to V1 or during the trial.
  • PUVA therapy within 4 weeks prior to V1.
  • UVB therapy within 2 weeks prior to V1 or during the trial.

Exclusion Criteria (for subjects performing HPA axis assessment):

  • A history of serious allergy, allergic asthma or serious allergic skin rash.
  • Known or suspected hypersensitivity to any component of CORTROSYN® (including ACTH/cosyntropin/tetracosactide)
  • Systemic treatment with corticosteroids (including inhaled and nasal steroids) within 12 weeks prior to SV2 or during the trial.
  • Oestrogen therapy (including contraceptives) or any other medication known to affect cortisol levels or HPA axis integrity within 4 weeks prior to SV2 or during the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02387853


Locations
Layout table for location information
United States, California
Lucile Packard Children's Hospital at Stanford
Palo Alto, California, United States, 94304
Redwood Family Dermatology
Santa Rosa, California, United States, 95403-2805
United States, Michigan
Hamzavi Dermatology
Fort Gratiot, Michigan, United States, 48059-3526
United States, New York
Greenwich Village Dermatology
New York, New York, United States, 10012
Skin Speciality Dermatology
New York, New York, United States, 10155
United States, Texas
Dermatology Treatment and Research Center PA
Dallas, Texas, United States, 75230-5808
Netherlands
UMC St Radboud
Nijmegen, Netherlands, 6525
Poland
MULTIKLINIKA SALUTE Sp zo.o.
Katowice, Poland, 40-123
Romania
Spitalul Clinic de Boli Infectioase si Tropicale
Bucharest, Romania, 030303
Sponsors and Collaborators
LEO Pharma
Investigators
Layout table for investigator information
Principal Investigator: M Seyger, MD UMC St Radboud
  Study Documents (Full-Text)

Documents provided by LEO Pharma:
Statistical Analysis Plan  [PDF] June 12, 2018
Study Protocol  [PDF] August 29, 2016


Layout table for additonal information
Responsible Party: LEO Pharma
ClinicalTrials.gov Identifier: NCT02387853     History of Changes
Other Study ID Numbers: LP0053-1108
First Posted: March 13, 2015    Key Record Dates
Results First Posted: January 15, 2019
Last Update Posted: January 15, 2019
Last Verified: January 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases